Pharmaceutisch Weekblad

, Volume 7, Issue 2, pp 63–66 | Cite as

Research in the Division of Pharmacology

  • D. D. Breimer
Article
  • 11 Downloads

Abstract

Within the Center for Bio-Pharmaceutical Sciences pharmacological research has its emphasis on kinetics of drug disposition, and its interrelationship with pharmacodynamics. The benzodiazepines present a class of related compounds where comparative studies have been performed. Both in humans and in animal models the relationship between plasma levels and central effects has been studied. Also the factors that influence individual responses to the same dose of a drug have been investigated. One of the approaches is the predictive value of antipyrine metabolite formation. Nifedipine shows polymorphism in oxidation, but it is possible to obtain the desired pharmacodynamic effect while minimizing side effects even in slow metabolizers.

Keywords

Public Health Internal Medicine Animal Model Plasma Level Nifedipine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Breimer DD. Developments in clinical pharmacokinetics 1981–1983. In: Aiache JM, Hirtz J, eds. 2nd European Congress of Biopharmaceutics and Pharmacokinetics. Paris: Technique et Documentation, 1984. Vol. 3.Google Scholar
  2. 2.
    Breimer DD, Jochemsen R, Von Albert HH. Pharmacokinetics of benzodiazepines: Short-acting versus long-acting. Arzneim Forsch 1980;30:875–81.Google Scholar
  3. 3.
    Jochemsen R, Van Boxtel CJ, Hermans J, Breimer DD. Pharmacokinetics of 5 benzodiazepine hypnotics in the same panel of healthy subjects. Clin Pharmacol Ther 1983;34:42–7.PubMedGoogle Scholar
  4. 4.
    Jochemsen R, Nandi KL, Corless D, Wesselman JGJ, Breimer DD. Pharmacokinetics of brotizolam in the elderly. Br J Clin Pharmacol 1983; 16:299S-307S.PubMedGoogle Scholar
  5. 5.
    Jochemsen R, Van Beusekom BR, Spoelstra P, Janssens AR, Breimer DD. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol 1983; 15:295–302.PubMedGoogle Scholar
  6. 6.
    Breimer DD, Jochemsen R, Kamphuisen HAC, Nicholson AN, Spencer MB, Stone BM. Central effects during the continuous osmotic infusion of a benzodiazepine (triazolam). Br J Clin Pharmacol (in press).Google Scholar
  7. 7.
    Danhof M, Levy G. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther 1984;229:44–50.PubMedGoogle Scholar
  8. 8.
    Dingemanse J, Breimer DD. Benzodiazepine receptors. Pharmacy International 1984;5:33–6.Google Scholar
  9. 9.
    Breimer DD, Danhof M. Interindividual differences in pharmacokinetics and drug metabolism. In: Breimer DD, ed. Towards Better Safety of Drugs and Pharmaceutical Products. Amsterdam: Elsevier/North-Holland Biomedical Press, 1980:117–42.Google Scholar
  10. 10.
    Danhof M, Teunissen MWE. Antipyrine as a model drug to assess oxidative drug metabolizing activity in man. Pharmacy International 1984;5:11–5.Google Scholar
  11. 11.
    Teunissen MWE, Spoelstra P, Koch CW, et al. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1984;18:707–15.PubMedGoogle Scholar
  12. 12.
    Teunissen MWE, Wahlén, A, Vinnars E, Breimer DD. The influence of alaproclate on antipyrine metabolite formation in man. Eur J Clin Pharmacol 1984;27:447–52.PubMedGoogle Scholar
  13. 13.
    Breimer DD. Interindividual variation in drug disposition: Clinical implications and methods of investigations. Clin Pharmacokinet 1983;8:371–7.PubMedGoogle Scholar
  14. 14.
    Van der Graaff M, Vermeulen NPE, Joeres RP, Vlietstra T, Breimer DD. Correlation betweenin vivo metabolism of hexobarbital and antipyrine in rats. J Pharmacol Exp Ther 1983;227:459–65.PubMedGoogle Scholar
  15. 15.
    Teunissen MWE, De Leede LGJ, Boeijinga JK, Breimer DD. Correlation between antipyrine metabolite formation and theophylline metabolism in man after simultaneous single dose administration and at steadystate. J Pharmacol Exp Ther (in press).Google Scholar
  16. 16.
    Kleinbloesem CH, Van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 1984;22:3721–4.Google Scholar
  17. 17.
    Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd JP, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984;35:742–9.PubMedGoogle Scholar
  18. 18.
    Kleinbloesem CH, Van Brummelen P, Van Harten J, Danhof M, Breimer DD. Nifedipine: Influence of renal function on pharmacokinetic/haemodynamic relationship. Clin Pharmacol Ther (in press).Google Scholar
  19. 19.
    De Leede LGJ, De Boer AG, Van Velzen SL, Breimer DD. Zero-order rectal delivery of theophylline in man with an osmotic system. J Pharmacokinet Biopharm 1982;10;525–36.PubMedGoogle Scholar
  20. 20.
    De Leede LGJ, De Boer AG, Feijen CD, Breimer DD. Site-specific rectal drug administration in man with an osmotic system: influence of ‘first-pass’ elimination of lidocaine. Pharm Res 1984;3:129–34.Google Scholar
  21. 21.
    Breimer DD, De Leede LGJ, De Boer AG. New drug delivery systems as tools in clinical pharmacology. In: Lemberger L, Reidenberg MM, eds. Proceedings 2nd World Conference on Clinical Pharmacology and Therapeutics. Bethesda: American Society of Pharmacology & Experimental Therapeutics, 1984:431–43.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1985

Authors and Affiliations

  • D. D. Breimer
    • 1
  1. 1.Center for Bio-Pharmaceutical Sciences, Sylvius LaboratoriesState University of LeidenThe Netherlands

Personalised recommendations